17. Sep 2026
Description
(AWP Alliance News) - MindMaze Therapeutics unveiled MindMotion Lite, a tablet-based home neurorehabilitation product slated for launch by year-end 2026, aiming to widen access to intensive therapy beyond clinics. The company is positioning the product as a lower-cost, easier-to-deploy format to accelerate scale-up in home care.
The launch extends its MindMotion platform into a more capital-efficient distribution model, potentially strengthening competitiveness in a market focused on post-stroke continuity of care. MindMotion Lite is expected to support commercial uptake by fitting within existing reimbursement codes tied to the company's current offering.
https://www.publicnow.com/view/DA2D84990CE27BB861AA875E0164F81A065B118D…
Disclaimer: This news brief was created using generative artificial intelligence. MindMaze Therapeutics Holding SA published the original content used to generate this news brief via EQS News on September 17, 2026, and is solely responsible for the information contained therein.
